Browse > Article

A Study on BRCA1/2 Mutations, Hormone Status and HER-2 Status in Korean Women with Early-onset Breast Cancer  

Choi, Doo-Ho (Departments of Radiation Oncology, Soonchunhyang University College of Medicine)
Jin, So-Young (Departments of Pathology, Soonchunhyang University College of Medicine)
Lee, Dong-Wha (Departments of Pathology, Soonchunhyang University College of Medicine)
Kim, Eun-Seog (Departments of Radiation Oncology, Soonchunhyang University College of Medicine)
Kim, Yong-Ho (Departments of Radiation Oncology, Soonchunhyang University College of Medicine)
Publication Information
Radiation Oncology Journal / v.26, no.1, 2008 , pp. 65-73 More about this Journal
Abstract
Purpose: Women with breast cancer diagnosed at an age of 40 years or younger have a greater prevalence of germline BRCA1 and BRCA2 mutations than the prevalence of women with breast cancer diagnosed at older ages. Several immunohistochemical characteristics have been identified in breast cancers from studies of Caucasian women with BRCA1/2 mutations having familial or early-onset breast cancers. The aim of this study is to determine whether early-onset breast cancer in BRCA1 or BRCA2 mutation carriers, who were not selected from a family history, could be distinguished by the use of immunohistochemical methods and could be distinguished from breast cancer in women of a similar age without a germline BRCA1 or BRCA2 mutation. We also analyzed the prognostic difference between BRCA1/2 related and BRCA1/2 non-related patients by the use of univariate and multivariate analysis. Materials and Methods: Breast cancer tissue specimens from Korean women with early-onset breast cancers were studied using a tumor tissue microarray. Immunohistochemical staining of estrogen receptor(ER), progesterone receptor(PR) and HER-2, as well as the histology and grade of these specimens, were compared. The prognostic impact of immunohistochemical and histological factors as well as the BRCA1/2 mutation status was investigated separately. Results: There were 14 cases and 16 deleterious BRCA1/2 mutations among 101 patients tested. A family history(4/14) and bilateral breast cancers(3/9) were high risk factors for BRCA1/2 mutations. BRCA1/2-associated cancers demonstrated more expression of ER-negative(19.4% versus 5.1%, p=0.038) and HER-2 negative than BRCA1/2 negative tumors, especially for tumors with BRCA1 tumors The BRCA1/2 mutation rate for patients with triple negative tumors(negative expression of ER, PR and HER-2) was 24.2%. Tumor size, nodal status, and HER-2 expression status were significantly associated with disease free survival, as determined by univariate and multivariate analysis, but the BRCA1/2 status was not a prognostic factor. Conclusion: Breast cancer that occurs in women with a germline BRCA1 or BRCA2 mutations have recognizable immunohistochemical features, which may be useful in identifying individuals that are more likely to carry germline mutations. Although the BRCA1/2 mutation status was not a prognostic factor in Korean women with early-onset breast cancer, more cases with a longer follow-up period are needed for further study.
Keywords
Breast cancer; BRCA1/2 mutation; Hormone receptor; HER-2;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 2000;59:185-192   DOI   ScienceOn
2 Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006;17:391-400   DOI   ScienceOn
3 Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-1668   DOI   PUBMED   ScienceOn
4 Park BW, Kim SI, Kim EK, Yang WI, Lee KS. Impact of patients age on the outcome of primary breast cancer. J Surg Oncol 2002;80:12-18   DOI   ScienceOn
5 Armed JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population- based study. Cancer Res 1999;59:2011-2017   PUBMED
6 Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847   DOI   ScienceOn
7 Palacious J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-3614   PUBMED
8 Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002;62:1481-1488   PUBMED
9 Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003;97:1-11   DOI   ScienceOn
10 Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000;63: 213-223   DOI   ScienceOn
11 Choi DH, Lee MH, Haffty BG. Is the BRCA germline mutation a prognostic factor in Korean patients with early-onset breast carcinomas? J Korean Soc Ther Radiol Oncol 2003;21:149-157
12 Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-371   DOI   ScienceOn
13 Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31   PUBMED
14 Lakhani SR, Easton DF, Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carries of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-1510   DOI   ScienceOn
15 Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG, and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarial cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514   PUBMED
16 Kang HC, Kim IJ, Park JH, et al. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat 2002;20:235   PUBMED
17 Ministry of Health and Welfare. Annual report of the Central Cancer Registry in Korea, Seoul. Ministry of Health and Welfare 2001
18 Erola H, Heikkaila P, Tamminen A, Aittomaki K, blomqvist C, Nevanlinna H. Histopathological features of breast tumors in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R93-100   DOI   ScienceOn
19 Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 2006;70:496-501   DOI   ScienceOn
20 Loman N, Johannsson O, Bendahl PO, Borg A, Femo M, Olsson H. Steroid receptors in hereditary breast carcinoma s associated with BRCA1or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-319   DOI   ScienceOn
21 Musolino A, Bella MA, Bortesi B et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 2007;16:280-292   DOI   ScienceOn
22 Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease free survival in women with operable breast cancer. BMC Cancer 2004;17:82
23 EL tamer M, Russo D, Troxel A, et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surgical Oncol 2004;11:157-164   DOI
24 Ahn SH, Son BH, Yoon KS, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 2007;245:90-95   DOI   ScienceOn
25 Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318   DOI   ScienceOn
26 Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004;22:1638-1645   DOI   ScienceOn
27 Choi DH, Lee MH, Haffty BG. Double heterozygotes for non_Caucasian families with mutations in BRCA-1 and BRCA-2 genes. Breast J 2006;12:216-220   DOI   ScienceOn
28 Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-752   DOI   ScienceOn
29 Johnnesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian Cancer patients. Cancer Res 1996;56:3663-3665
30 Eerola H, Vahteristo P, Sarantaus L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 2001;93:368-372   DOI   ScienceOn
31 Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-, and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867-876   DOI   ScienceOn